Drug intelligence / Profile preview

CMS-F021 Gel

Development stage: Phase 1
Lead developer: Hainan Demei Pharmaceutical Technology
Modality: Small Molecules
Administration: Topical

Overview

CMS-F021 Gel is a topical antimicrobial candidate developed by Hainan Demei Pharmaceutical Technology, a subsidiary of China Medical System (CMS). It is intended for the treatment of superficial skin and soft tissue infections (SSTIs) caused by Gram-positive bacteria. The drug is currently undergoing Phase 1 clinical trials in China to evaluate its safety, tolerability, local irritation, and pharmacokinetic profile across various concentrations (0.2%, 0.6%, and 1.2%). As a topical formulation, it aims to provide effective antibacterial activity at the site of infection while minimizing systemic exposure.

Beyond the preview

Go deeper on CMS-F021 Gel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CMS-F021 Gel.

Explore the full profile